Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy
- PMID: 32841387
- PMCID: PMC7461061
- DOI: 10.1002/jmv.26459
Anxiety and depression symptoms after virological clearance of COVID-19: A cross-sectional study in Milan, Italy
Abstract
Prevalence of anxiety or depression was investigated in 105 coronavirus disease 2019 (COVID-19) patients at 1 to 3 months from virological clearance by hospital anxiety and depression scale (HADS-A/D). 30% of patients displayed pathological HADS-A/D, 52.4% showed persistent symptoms. Pathological patients with HADS-A/D more commonly reported symptom persistence, even after adjustment for age, gender, and disease severity. Psychological assessments should be encouraged in COVID-19 patients' follow-up.
Keywords: COVID-19; anxiety and depression symptoms; hospital anxiety and depression scale.
© 2020 Wiley Periodicals LLC.
Conflict of interest statement
The authors declare that there are no conflict of interests.
References
-
- Rogers JP, Chesney E, Oliver D, et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta‐analysis with comparison to the COVID‐19 pandemic. Lancet Psychiatry. 2020;7(7):611‐627. 10.1016/S2215-0366(20)30203-0 - DOI - PMC - PubMed
